MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study
In participants with PAH on stable background therapy, including PDE5i, inhaled MK-5475 reduced PVR and was well tolerated, without evidence of systemic side-effects such as hypotension, suggesting a pulmonary selective pharmacodynamic effect.
Authors
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Paul M. Hassoun (ORCID: https://orcid.org/0000-0003-0601-4975)
- María José Loureiro (ORCID: https://orcid.org/0000-0002-5430-5585)
- Wei Fu (ORCID: https://orcid.org/0009-0004-6087-6183)
- Guillermo Bortman (ORCID: https://orcid.org/0000-0003-4437-6854)
- Carmen La Rosa
- Kelly Chin (ORCID: https://orcid.org/0000-0002-1214-6723)
- Marc Humbert (ORCID: https://orcid.org/0000-0003-0703-2892)
- Mahesh J. Patel
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Johns Hopkins University (US)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Johns Hopkins Medicine (US)
- Medizinische Hochschule Hannover (DE)
- Hospital de Niños de la Santísima Trinidad (AR)
- Bicêtre Hospital (FR)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1183/13993003.01110-2024
- Citations
- 12
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.03